TCGA-66-2744-01A-01R-0980-07
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 71
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.660
- INTERFERON_GAMMA_RESPONSE+0.610
- ALLOGRAFT_REJECTION+0.600
- IL6_JAK_STAT3_SIGNALING+0.570
- INFLAMMATORY_RESPONSE+0.560
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.490
- COMPLEMENT+0.460
- TNFA_SIGNALING_VIA_NFKB+0.440
- E2F_TARGETS+0.430
- ANGIOGENESIS+0.380
Top 10 suppressed
- NOTCH_SIGNALING-0.160
- PEROXISOME-0.140
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.140
- BILE_ACID_METABOLISM-0.110
- PROTEIN_SECRETION-0.080
- ESTROGEN_RESPONSE_EARLY-0.060
- ADIPOGENESIS-0.050
- HEME_METABOLISM-0.030
- OXIDATIVE_PHOSPHORYLATION-0.020
- FATTY_ACID_METABOLISM-0.010
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | R409 | — | — | 0.941 |
| 2 | SRR1516055 | — | — | 0.911 |
| 3 | AUR-AFUI-TTP1-A-1-0-R-A743-41 | — | C | 0.902 |
| 4 | TCGA-FD-A3B3-01A-12R-A206-07 | — | — | 0.900 |
| 5 | R303 | — | — | 0.892 |
| 6 | SRR29022839 | — | A | 0.889 |
| 7 | TCGA-22-5489-01A-01R-1635-07 | — | cohortSQ1 | 0.884 |
| 8 | BS_6WP1FHTE | high-grade glioma | — | 0.882 |
| 9 | s0112234 | — | — | 0.882 |
| 10 | BS_J1AB8PMA | Med | Medulloblastoma | 0.880 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 40 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.660 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.610 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.600 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.570 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.560 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.490 | Inavolisib | — uncovered |
| COMPLEMENT | 0.460 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.440 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.430 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.380 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.380 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.380 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.350 | Idelalisib | — uncovered |
| COAGULATION | 0.340 | Binimetinib | — uncovered |
| APICAL_JUNCTION | 0.330 | Inavolisib | — uncovered |
| APOPTOSIS | 0.330 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.310 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.310 | Cobimetinib | — uncovered |
| HYPOXIA | 0.280 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.260 | Inavolisib | — uncovered |